Crescent Diagnostics is an early stage diagnostics company incorporated in the UK, with a laboratory in Derry, Northern Ireland and offices at University College Dublin in the Republic of Ireland. The company is a spin-out of the University of Limerick and founded upon research conducted by the Crescent co-founder Dr Mark Towler, currently Professor of Biomedical Engineering, Ryerson University, Toronto, Canada.
Crescent Diagnostics has developed BQT® (Bone Quality Test) as a screening technology for assessing the risk of osteoporosis. Osteoporosis represents a significant challenge around the world affecting one in three women and one in five men over fifty. The cost of hip fractures resulting from osteoporosis is estimated at €36 billion annually to treat in the EU.
BQT® will be marketed as an over-the-counter test in the UK and the Republic of Ireland under the name Osentia®. It will be sold through pharmacies and other retail outlets and through the internet, using a consumer-to-lab business model.
BQT® analyses the keratin structure in nail clippings using Raman spectrometry. The analysis of keratin is able to is able to differentiate between people showing a risk of fragility fracture and those that do not.